Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ornithine-Transcarbamylase Deficiency - Overview
Ornithine-Transcarbamylase Deficiency - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ornithine-Transcarbamylase Deficiency - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ornithine-Transcarbamylase Deficiency - Companies Involved in Therapeutics Development
Arcturus Therapeutics Ltd
Lucane Pharma SA
Promethera Biosciences SA
Selecta Biosciences Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG
Ornithine-Transcarbamylase Deficiency - Drug Profiles
ARCT-810 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Ornithine Transcarbamylase for Ornithine Transcarbamylase Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Ornithine Transcarbamylase for Ornithine Transcarbamylase Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Ornithine Transcarbamylase for Ornthine Transcarbamylase Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Ornithine Transcarbamylase for Ornthine Transcarbamylase Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium benzoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Liver Failure, Type 1 Diabetes and Urea Cycle Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ornithine-Transcarbamylase Deficiency - Dormant Projects
Ornithine-Transcarbamylase Deficiency - Discontinued Products
Ornithine-Transcarbamylase Deficiency - Product Development Milestones
Featured News & Press Releases
Jun 05, 2020: Arcturus Therapeutics announces first healthy volunteer dosed in phase 1 study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
Apr 13, 2020: Arcturus Therapeutics announces allowance of IND & approval of clinical trial application (CTA) for ARCT-810, a first-in-class investigatiol mR medicine to treat ornithine transcarbamylase deficiency
Oct 23, 2019: Selecta Biosciences presents new preclinical data from its gene therapy program at 2019 ESGCT Annual Congress
Apr 16, 2019: Selecta Biosciences presents new preclinical data of SEL-313 from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Oct 05, 2018: Co-administration of AAV Vectors with SVP-Rapamycin Ebles Vector Re-administration in Pre-clinical Gene Therapy Study Published in ture Communications by Genethon and Selecta Biosciences
Oct 05, 2017: Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations on SEL-313
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Ornithine-Transcarbamylase Deficiency, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Arcturus Therapeutics Ltd, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Lucane Pharma SA, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Promethera Biosciences SA, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Selecta Biosciences Inc, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020
Ornithine-Transcarbamylase Deficiency - Pipeline by Unicyte AG, H1 2020
Ornithine-Transcarbamylase Deficiency - Dormant Projects, H1 2020
Ornithine-Transcarbamylase Deficiency - Discontinued Products, H1 2020